Volume | 2,915 |
|
|||||
News | - | ||||||
Day High | 3.4045 | Low High |
|||||
Day Low | 3.20 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aspira Womans Health Inc | AWH | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.33 | 3.20 | 3.4045 | 3.40 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
38 | 2,915 | $ 3.34 | $ 9,750 | - | 2.3087 - 6.75 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:11:06 | 1 | $ 3.14 | USD |
Aspira Womans Health Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
41.35M | 10.34M | - | 9.15M | -16.69M | -1.61 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aspira Womans Health News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AWH Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.52 | 3.57 | 3.20 | 3.46 | 6,503 | -0.14 | -3.98% |
1 Month | 3.50 | 3.675 | 2.51 | 3.03 | 25,014 | -0.12 | -3.43% |
3 Months | 5.36 | 5.45 | 2.51 | 3.75 | 23,721 | -1.98 | -36.94% |
6 Months | 5.36 | 5.65 | 2.49 | 3.85 | 36,617 | -1.98 | -36.94% |
1 Year | 5.325 | 6.75 | 2.3087 | 4.14 | 66,651 | -1.95 | -36.53% |
3 Years | 90.75 | 95.85 | 2.3087 | 25.84 | 430,032 | -87.37 | -96.28% |
5 Years | 62.10 | 158.10 | 2.3087 | 43.99 | 505,758 | -58.72 | -94.56% |
Aspira Womans Health Description
Aspira Womens Health Inc is transforming women's health with the discovery, development, and commercialization of testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-cleared products OVA1 and OVERA to detect the risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. Its focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment. |